The Potential Efficacy of Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma Patients with Macroscopic Portal Vein Tumor Thrombus

Overview

Journal Surg Today

Specialty General Surgery

Date 2025 Feb 11

PMID 39934306

Authors

Shohei Komatsu

Yoshihiko Yano

Kazuki Terashima

Yoshimi Fujishima

Jun Ishida

Nobuaki Ishihara

Takanori Matsuura

Tomoaki Okimoto

Yuzo Kodama

Takumi Fukumoto

Affiliations

Soon will be listed here.

Abstract

Purpose: The prognosis of patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) in the first-order or main trunk/contralateral branches (Vp3/4) is poor. The present study aimed to clarify the real-world data of atezolizumab plus bevacizumab treatment (Ate/bev) for HCC patients with Vp3/4 PVTT.

Methods: The subjects of this study were 22 consecutive HCC patients with Vp3/4 PVTT, who were treated with Ate/bev. Survival rates and radiological responses were evaluated based on the modified albumin-bilirubin (mALBI) grade [mALBI 1 + 2a (1/2a) versus 2b + 3 (2b/3)] using the modified Response Evaluation Criteria in Solid Tumors.

Results: The median survival time of the 22 patients was 15.0 months, with 1- and 2-year survival rates of 62.7% and 49.3%, respectively. The objective response (OR) rates of patients with mALBI 1/2a and 2b/3 were 91.7% (11/12) and 10.0% (1/10), respectively, with a significant difference (p < 0.001). The 2-year survival rates of patients with mALBI 1/2a and 2b/3 were 78.6% and 20.0%, respectively, with a significant difference (p = 0.0041).

Conclusion: Ate/bev was effective for treating HCC patients with Vp3/4 PVTT. OR rate and MST were favorable, particularly for patients with preserved liver function (mALBI 1/2a), suggesting its great potential for the treatment of HCC in patients with Vp3/4 PVTT.

References

Marrero J, Kulik L, Sirlin C, Zhu A, Finn R, Abecassis M . Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68(2):723-750. DOI: 10.1002/hep.29913. View

Lu J, Zhang X, Zhong B, Lau W, Madoff D, Davidson J . Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. Lancet Gastroenterol Hepatol. 2019; 4(9):721-730. DOI: 10.1016/S2468-1253(19)30178-5. View

Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A . BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2021; 76(3):681-693. PMC: 8866082. DOI: 10.1016/j.jhep.2021.11.018. View

Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M . Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016; 65(5):938-943. DOI: 10.1016/j.jhep.2016.05.044. View

Yoshidome H, Takeuchi D, Kimura F, Shimizu H, Ohtsuka M, Kato A . Treatment strategy for hepatocellular carcinoma with major portal vein or inferior vena cava invasion: a single institution experience. J Am Coll Surg. 2011; 212(5):796-803. DOI: 10.1016/j.jamcollsurg.2011.01.002. View

Ban D, Shimada K, Yamamoto Y, Nara S, Esaki M, Sakamoto Y . Efficacy of a hepatectomy and a tumor thrombectomy for hepatocellular carcinoma with tumor thrombus extending to the main portal vein. J Gastrointest Surg. 2009; 13(11):1921-8. DOI: 10.1007/s11605-009-0998-0. View

Komatsu S, Kido M, Kuramitsu K, Tsugawa D, Gon H, Fukushima K . Impact of Hepatectomy for Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombus. J Gastrointest Surg. 2021; 26(4):822-830. DOI: 10.1007/s11605-021-05181-0. View

Hata M, Tokuuye K, Sugahara S, Kagei K, Igaki H, Hashimoto T . Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer. 2005; 104(4):794-801. DOI: 10.1002/cncr.21237. View

Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20):1894-1905. DOI: 10.1056/NEJMoa1915745. View

10.

Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K . Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. Liver Cancer. 2019; 8(2):121-129. PMC: 6465715. DOI: 10.1159/000488778. View

11.

Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N . Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer. 2017; 6(4):325-336. PMC: 5704689. DOI: 10.1159/000479984. View

12.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

13.

Lencioni R, Llovet J . Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1):52-60. DOI: 10.1055/s-0030-1247132. View

14.

Llovet J, Bustamante J, Castells A, Vilana R, Ayuso M, Sala M . Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1998; 29(1):62-7. DOI: 10.1002/hep.510290145. View

15.

Villa E, Moles A, Ferretti I, Buttafoco P, Grottola A, Del Buono M . Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology. 2000; 32(2):233-8. DOI: 10.1053/jhep.2000.9603. View

16.

Kudo M, Finn R, Qin S, Han K, Ikeda K, Piscaglia F . Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391(10126):1163-1173. DOI: 10.1016/S0140-6736(18)30207-1. View

17.

Abou-Alfa G, Lau G, Kudo M, Chan S, Kelley R, Furuse J . Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 2024; 1(8):EVIDoa2100070. DOI: 10.1056/EVIDoa2100070. View

18.

Kuzuya T, Ishigami M, Ito T, Ishizu Y, Honda T, Ishikawa T . Sorafenib . Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. Anticancer Res. 2020; 40(4):2283-2290. DOI: 10.21873/anticanres.14193. View

19.

Ishihara N, Komatsu S, Sofue K, Ueshima E, Yano Y, Fujishima Y . Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma. Hepatol Res. 2024; 54(8):773-780. DOI: 10.1111/hepr.14024. View

20.

Huang C, Zhu X, Shen Y, Wu D, Ji Y, Ge N . Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. Biomark Res. 2021; 9(1):19. PMC: 7981986. DOI: 10.1186/s40364-021-00274-z. View